EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy

Sara S Bashraheel iD, Sayed K Goda

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241310507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Sara S Bashraheel und 1 weiteren Autor:innen. Beteiligte Einrichtung: QU Health, Qatar University (QU), Doha P.O. Box 2713, Qatar. Hauptthemen laut MEDLINE: Superantigens, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacterial superantigens (SAgs) are effective T-cell stimulatory molecules that lead to massive cytokine production. Superantigens crosslink between MHC class II molecules on the Antigen Presenting Cells (APC) and TCR on T-cells. This enables them to activate up to 20% of resting T cells, whilst conventional antigen presentation results in the activation of 0.001–0.0001% of the T cell population. These biological properties of superantigens make them attractive for use in immunotherapy. Previous studies have established the effectiveness of superantigens as therapeutic agents. This, however, was achieved with severe side effects due to the high lethality of the native toxins. Our study aims to produce superantigen-based peptides with minimum or no lethality for safer cancer treatment. In previous work, we designed and synthesized twenty overlapping SPEA-based peptides and successfully mapped regions in SPEA superantigen, causing a vasodilatory response. We screened 20 overlapping SPEA-based peptides designed and synthesized to cover the whole SPEA molecule for T-cell activation and tumor-killing ability. In addition, we designed and synthesized tumor-targeted superantigen-based peptides by fusion of TGFαL3 either from the N′ or C′ terminal of selected SPEA-based peptides with an eight-amino acid flexible linker in between. Our study identified parts of SPEA capable of stimulating human T-cells and producing different cytokines. We also demonstrated that the SPEA-based peptide conjugate binds specifically to cancer cells and can kill this cancer. Peptides induce T-cell activation, and tumor killing might pave the way for safer tumor-targeted superantigens (TTS). We proposed the combination of our new superantigen-based peptide conjugates with other immunotherapy techniques for effective and safer cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SuperantigensNeoplasmsHumansPeptidesT-LymphocytesImmunotherapyEnterotoxins

Stichwörter der Autor:innen

SPEA superantigencancer combination therapysuperantigen-based peptide agonistsuperantigen-based peptide conjugatetargeted cancer immunotherapy

Substanzen

SuperantigensPeptidesEnterotoxins

Autor:innen und Institutionen

  • QU Health, Qatar University (QU), Doha P.O. Box 2713, Qatar.
  • College of Science and Technology, University of Derby, Derby DE22 1GB, UK.

ORCID-Profile: Sara S Bashraheel

Zitieren

APA

Bashraheel, S. S., & Goda, S. K. (2023). Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310507

Vancouver

Bashraheel SS, Goda SK. Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310507

BibTeX
@article{Bashraheel2023,
  author = {Bashraheel, Sara S and Goda, Sayed K},
  title = {Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241310507}
}
Kostenlos starten →